LXX.CN - Lexaria Bioscience Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
1.4300
+0.0300 (+2.14%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.4000
Open0.0000
Bid1.41 x 0
Ask1.50 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume99,861
Market Cap111.671M
Beta (3Y Monthly)5.27
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire17 days ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Capitalizing on Technology in CBD-Infused Products

    NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Booming Cannabis Consumables Space Continues to see Product Innovations,” featuring Lexaria Bioscience Corp. (CSE:LXX) (LXRP). Capitalizing on its bioavailability-enhancing technology and established presence as a CBD-infused product developer, Lexaria has now moved to tackle the U.S. soft drinks market, which is expected to be worth $388 billion-plus by 2025, introducing a discreet, single-serving foil packet cannabinoid drink powder named ChrgD+. Lexaria is confident that a small two-gram foil packet that can be discreetly carried in a shirt pocket or purse for incorporation into a beverage will be a big hit.

  • GlobeNewswire18 days ago

    CannabisNewsWire Announces Growing Cannabis Acceptance Setting Stage For Consumable Cannabis Boom

    NEW YORK, Nov. 29, 2018 -- via CannabisNewsWire -- CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an.

  • ACCESSWIRE21 days ago

    Lexaria Bioscience Submits Application to Health Canada for Research License and Appoints Chief Legal Officer

    KELOWNA, BC / ACCESSWIRE / November 26, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has submitted a Health Canada research application, and appointed Dr. Ed Ergenzinger to its executive team. The Company has submitted its research application under Health Canada's Cannabis Tracking and Licensing System for the operation of a Kelowna-based R&D laboratory within Lexaria's new head office under construction, to work with cannabinoids. The laboratory will enhance Lexaria's ability to formulate for analytical purposes, various products that may contain cannabinoids or other controlled substances.

  • GlobeNewswirelast month

    Lexaria Targets Cannabinoids, Tobacco, Hemp, and Pharma Markets with New Subsidiaries -- CFN Media

    SEATTLE, Nov. 13, 2018 -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry,.

  • ACCESSWIRElast month

    Lexaria Bioscience Launches ChrgD+

    KELOWNA, BC / ACCESSWIRE / November 13, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the launch of ChrgD+, a water-soluble, ready-mix hemp supplement powder packet formulation designed to be added to any drink, in any location, creating many innovative-use applications. Consistent with other Lexaria formulations, ChrgD+ incorporates multi-spectrum hemp oil processed using the Company's patented DehydraTECHTM technology, allowing effective delivery of hemp oil into any existing beverage, hot or cold. "This new delivery format is truly unique in its performance," said Chris Bunka, CEO of Lexaria Bioscience.

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Announces Increased Size and Closing of Private Placement

    KELOWNA, BC / ACCESSWIRE / October 31, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that due to strong demand it has increased the size of its previously announced non-brokered private placement, closing on gross proceeds of US$1,515,440 (the "Offering"). Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to acquire one common share of the Company at a price of US$2.25 per common share for a period of 24 months following the closing of the Offering.

  • GlobeNewswire2 months ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp.’s Invaluable Technology for Cannabis Companies That Are Shifting Focus from Smoking

    NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Canada Leads International Cannabis Boom — and It’s Not About Smoking,” featuring Lexaria Bioscience Corp. (CSE:LXX) (LXRP). Lexaria’s patented technology could be invaluable for companies catering to this desire. Its lipophilic enhancement technology is designed to improve the biological conductivity of active compounds, including those found in cannabis.

  • GlobeNewswire2 months ago

    CannabisNewsWire Announces Publication on Abundant Opportunities as Canada Becomes First G20 Nation to Legalize Recreational Cannabis

    NEW YORK, Oct. 23, 2018 -- via CannabisNewsWire – CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an.

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Receives Two New Granted Patents

    KELOWNA, BC / ACCESSWIRE / October 18, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has been granted two new US patents. Lexaria now has six granted patents in the US and four granted patents in Australia. All ten of these patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof".

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Creates and Brands Subsidiary Companies

    KELOWNA, BC / ACCESSWIRE / October 10, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce it has completed the creation of four wholly-owned subsidiary companies. This new corporate structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each. The subsidiaries are each empowered with Lexaria's patented DehydraTECHTM technology.

  • GlobeNewswire2 months ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Among World’s Biggest Holders of Cannabis Patents

    NEW YORK, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector,” featuring Lexaria Bioscience Corp. (CSE:LXX) (LXRP). Outside of China, Lexaria is one of the world’s biggest holders of cannabis patents with eight patents already granted. The company currently holds four patents in the United States and four in Australia, covering aspects of its work to make beneficial drugs more palatable and effective.

  • GlobeNewswire2 months ago

    CannabisNewsWire Announces IP and Intangible Assets, Particularly in Pharma Sector, Increasingly Dominate Global Business Landscape

    NEW YORK, Oct. 05, 2018 -- via CannabisNewsWire – CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an.

  • GlobeNewswire2 months ago

    The Race to Speed Up the Effects of Cannabis -- CFN Media

    SEATTLE, Oct. 03, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Biosciences Inc. The company has developed an innovative drug delivery platform that increases intestinal absorption rates, rapidly delivers active ingredients to the bloodstream, and provides taste-masking benefits. The cannabis industry is heating up with the legalization of medical and recreational cannabis across Canada and a growing number of states.

  • ACCESSWIRE3 months ago

    Lexaria Files New Patent Application for Delivery of Tobacco-Derived Products

    KELOWNA, BC / ACCESSWIRE / September 28, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the filing of a new strategic patent application. The new provisional patent application is entitled "Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof". This application represents Lexaria's tenth patent family and expands the applicability of the already-patented DehydraTECHTM technological process to impart benefits to tobacco leaves that may be utilized to deliver compounds that may or may not include nicotine.

  • ACCESSWIRE3 months ago

    Lexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance

    KELOWNA, BC / ACCESSWIRE / September 7, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company"or "Lexaria"), a drug delivery platform innovator, announces strategic additions to its patent portfolio. Three new Australian patents were granted to Lexaria by the Australian Patent Office, bringing the Company's worldwide patent portfolio to eight issued patents: four each in the US and Australia.

  • ACCESSWIRE4 months ago

    Lexaria Bioscience Announces Positive Blood-Brain-Barrier Results

    Lexaria's technology delivered 195% more nicotine across the blood-brain-barrier conceptually allowing for smaller micro doses in accordance with developing FDA policies. Lexaria's formulation was 4x faster at reaching its peak level in brain tissue than the non-enhanced control formulation. KELOWNA, BC / ACCESSWIRE / August 30, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces further results from its recently completed second-generation study in 40 rats (two groups of 20 each) in addition to those released on August 7, 2018.

  • ACCESSWIRE4 months ago

    Lexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing: Delivery Measured Within Minutes

    This study represents Lexaria's second in vivo nicotine study, building on the previous nicotine breakthrough study announced April 17, 2018. CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has successfully delivered nicotine in an edible form into blood plasma just minutes after dosing in an animal in vivo study. Speed of onset is a key attribute for oral drug administration, and it is of particular importance for the consideration of non-inhalation nicotine delivery formats.

  • ACCESSWIRE5 months ago

    Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

    KELOWNA, BC / ACCESSWIRE / August 1, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to report ...

  • ACCESSWIRE5 months ago

    Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages

    "Hill Street") jointly announced that they have signed a Definitive Agreement to license Lexaria's DehydraTECHTM, on a semi-exclusive basis, for a term of five (5) years, to produce a line of cannabis-infused alcohol-free beverages for Canadian distribution, following regulatory approval. The Definitive Agreement is the conclusion of the process begun following the announcement of the non-binding letter of intent in April 2018. Terms of the Definitive Agreement were not disclosed.

  • ACCESSWIRE5 months ago

    Lexaria Announces 2018 AGM Results and Corporate Update

    KELOWNA, BC / ACCESSWIRE / July 3, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special ...

  • CNW Group6 months ago

    Horizons ETFs Completes Rebalances of its Marijuana-focused ETFs

    TORONTO , June 29, 2018 /CNW/ - Horizons ETFs Management (Canada ) Inc. (" Horizons ETFs ") has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences ...